Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This interventional study is a single-center, open label, 26-week study, designed to evaluate
the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to
age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study
treatment will be administered by intravitreal injections.
Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit
2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection,
week 17, week 26.
Exams will look for continuous changes in visual acuity, change in area of geographic atrophy
lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in
reading speed, and change in microperimetry response.